Related Experiment Video
Updated: Jul 16, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Walter Jonat1, Christoph Mundhenke
1Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum S-H, Campus Kiel, Germany. jonat@email.uni-kiel.de
Abstract:
The adjuvant Femara versus Anastrozole Clinical Evaluation (FACE) trial compares upfront therapy letrozole 2.5 mg with anastrozole 1 mg daily for up to 5 years in postmenopausal, hormone receptor-positive, node-positive breast cancer patients. This phase III b open label, randomized, multicenter study will include 4000. patients from up to 250 international sites. Patients will be stratified by degree of lymph node involvement and HER-2 status. Any efficacy and safety difference of the two drugs will be reported. Primary objective is DFS, secondary objectives are safety, OS, time to distant metastases, time to contralateral breast cancer and breast cancer specific survival.
Related Concept Videos
Treatment Resistant Cancers
Clinical Trials: Overview
Treatment Resistent Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...